Recalls / Active ingredient / Ranibizumab
Ranibizumab
1 FDA drug recall involving the active ingredient “Ranibizumab”.
| Date | Class | Product | Firm |
|---|---|---|---|
| 2022-10-18 | Class III | Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial | Genentech Inc |